Warby Parker
WRBY
25.31
-0.92
-3.51%
Warby Parker
US · WRBY
#2446 by market cap
Listed 2021
25.31
-0.92
-3.51%
Live - 5344 symbols - heartbeat 538s ago
· 2026-10-08 07:40
Pre-market
25.48
+0.67%
After-hours
25.31
0.00%
Overnight
25.25
-0.24%
- Market cap
- 3.13B
- P/E (TTM)i
- 421.83
- P/Bi
- 7.98
- EPSi
- 0.01
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on WRBY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.51, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +13.04% YoY
Margins
- Gross margin
- 53.97%
- Operating margin
- -0.61%
- Net margin
- 0.19%
Key ratios & quality
- Altman Z-Scorei
- 5.51
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 370.46M | 393.72M | 540.80M | 598.11M | 669.77M | 771.32M | 871.91M |
| Gross profit | 223.11M | 231.94M | 317.75M | 341.06M | 365.22M | 426.83M | 470.58M |
| Selling & admin expenses | 224.77M | 287.57M | 461.41M | 452.27M | 437.22M | 456.95M | 475.92M |
| Research & development | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -1.66M | -55.63M | -143.66M | -111.20M | -72.00M | -30.11M | -5.34M |
| Pretax profit | 276.00K | -55.73M | -144.01M | -109.90M | -62.76M | -19.52M | 3.04M |
| Tax | 276.00K | 190.00K | 263.00K | 497.00K | 433.00K | 875.00K | 1.40M |
| Net profit | 0 | -55.92M | -144.27M | -110.39M | -63.20M | -20.39M | 1.64M |
| Basic EPS | -5 | -5 | -2 | -1 | -1 | 0 | 0 |
| Diluted EPS | -5.16 | -5.02 | -2.21 | -0.96 | -0.54 | -0.17 | 0.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 223.78M | 214.48M | 221.68M | 211.97M | 242.45M | 235.51M |
| Gross profit | 125.98M | 113.61M | 119.95M | 111.04M | 131.04M | 136.46M |
| Selling & admin expenses | 123.51M | 114.37M | 112.89M | 128.61M | 129.37M | 129.44M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.47M | -4.53M | 3.57M | -6.85M | 1.67M | 3.17M |
| Pretax profit | 4.93M | -2.54M | 5.75M | -5.09M | 4.00M | 5.25M |
| Tax | 1.45M | -789.00K | -125.00K | 862.00K | 821.00K | 607.00K |
| Net profit | 3.47M | -1.75M | 5.87M | -5.95M | 3.18M | 4.64M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.03 | -0.01 | 0.05 | -0.05 | 0.03 | 0.04 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 91.68M | 359.93M | 327.98M | 294.57M | 298.62M | 326.05M | 352.44M |
| Cash & ST investments | 55.42M | 314.09M | 256.42M | 208.59M | 216.89M | 254.16M | 286.36M |
| Inventory | 28.44M | 38.47M | 57.10M | 68.85M | 62.23M | 52.35M | 44.51M |
| Total assets | 175.86M | 444.75M | 440.65M | 568.71M | 580.31M | 676.49M | 720.92M |
| Total current liabilities | 75.87M | 105.33M | 118.10M | 129.56M | 127.09M | 130.35M | 150.13M |
| Short-term debt | -- | -- | -- | 22.55M | 24.29M | 20.24M | 31.40M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 102,460,000.00 | 136,338,000.00 | 154,648,000.00 | 282,061,000.00 | 278,525,000.00 | 336,417,000.00 | 353,189,000.00 |
| Total equity | 73.40M | 308.41M | 286.00M | 286.65M | 301.79M | 340.07M | 367.73M |
| Retained earnings | -269.47M | -325.39M | -493.24M | -603.63M | -666.83M | -687.22M | -685.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 330.60M | 346.10M | 344.06M | 352.44M | 357.69M | 370.84M |
| Cash & ST investments | 265.07M | 286.38M | 280.36M | 286.36M | 288.25M | 292.67M |
| Inventory | 48.61M | 43.27M | 45.59M | 44.51M | 46.45M | 42.10M |
| Total assets | 682.76M | 701.90M | 706.92M | 720.92M | 736.41M | 772.32M |
| Total current liabilities | 122.61M | 135.53M | 132.07M | 150.13M | 153.28M | 163.48M |
| Short-term debt | 18.88M | 24.63M | 28.64M | 31.40M | 31.88M | 35.54M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 328,666,000.00 | 340,448,000.00 | 337,296,000.00 | 353,189,000.00 | 360,604,000.00 | 380,330,000.00 |
| Total equity | 354.09M | 361.45M | 369.63M | 367.73M | 375.81M | 391.99M |
| Retained earnings | -683.75M | -685.50M | -679.63M | -685.58M | -682.40M | -677.76M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 21.39M | 32.76M | -31.99M | 10.37M | 60.99M | 98.74M | 110.79M |
| Depreciation & amortization | 14.52M | 17.76M | 21.55M | 31.86M | 38.55M | 45.87M | 50.28M |
| Free cash flow | -11.24M | 12.69M | -80.51M | -49.81M | 7.32M | 34.71M | 43.74M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -79.47M | 0 | -8.09M | -- | -- | -- | -- |
| Ending cash balance | 55.42M | 314.09M | 256.42M | 208.59M | 216.89M | 254.16M | 286.36M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 29.36M | 40.20M | 17.97M | 23.25M | 24.51M | 29.62M |
| Depreciation & amortization | 12.16M | 12.49M | 12.53M | 13.10M | 13.77M | 14.07M |
| Free cash flow | 13.21M | 23.91M | -1.52M | 8.13M | 8.37M | 6.76M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 265.07M | 286.38M | 280.36M | 286.36M | 288.25M | 292.67M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -358.15 | -38.56 | -21.48 | -6.35 | 0.46 |
| ROA %i | -32.72 | -18.02 | -35.56 | -21.87 | -11.00 | -3.24 | 0.23 |
| ROIC %i | -- | -- | -358.15 | -24.01 | -13.50 | -3.91 | 0.28 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -84.81 |
| EBIT margin %i | -0.45 | -14.13 | -26.56 | -18.59 | -10.75 | -3.90 | -0.61 |
| FCF / sales %i | -- | 3.22 | -- | -- | 1.09 | 4.50 | 5.02 |
| Current ratioi | 1.21 | 3.42 | 2.78 | 2.27 | 2.35 | 2.50 | 2.35 |
| Quick ratioi | 0.75 | 2.99 | 2.18 | 1.62 | 1.72 | 1.96 | 1.93 |
| Debt / assetsi | -- | -- | 0.00 | 30.49 | 30.06 | 33.31 | 32.34 |
| LT debt / equityi | -- | -- | -- | 52.62 | 49.76 | 60.32 | 54.86 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 17.31 | 19.37 | 12.56 | 13.39 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -16.75 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -4.25 | -2.67 | 0.20 | 0.46 | 0.37 | 2.06 |
| ROA %i | -2.23 | -1.40 | 0.11 | 0.23 | 0.19 | 1.05 |
| ROIC %i | -2.65 | -1.66 | 0.13 | 0.28 | 0.23 | 1.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2.83 | -2.20 | -0.93 | -0.61 | -0.69 | 0.17 |
| FCF / sales %i | 5.34 | 6.38 | 4.44 | 5.02 | 4.37 | 2.39 |
| Current ratioi | 2.70 | 2.55 | 2.61 | 2.35 | 2.33 | 2.27 |
| Quick ratioi | 2.17 | 2.12 | 2.13 | 1.93 | 1.89 | 1.80 |
| Debt / assetsi | 32.76 | 32.54 | 32.89 | 32.34 | 32.27 | 32.50 |
| LT debt / equityi | 57.83 | 56.37 | 55.16 | 54.86 | 54.75 | 54.96 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Eyewear is the largest reported line at 81.42% of revenue, across 3 reported segments.
- The next-largest line, Contacts, is a distant second at 11.29% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Eyewear81.42%
Contacts11.29%
Eye care7.28%
Quote time 2026-10-08 07:40:26 · For reference only, not investment advice and not tailored to your situation.